Selective Progesterone Receptor Modulators (SPRMs) and Androgen Receptor Modulators (SARMs) as Treatment for Benign Gynecologic Diseases

Md Soriful Islam, Lena W Chen, James H Segars
Clinical obstetrics and gynecology · 2021 · vol. 64(4) , pp. 813–836 · doi:10.1097/grf.0000000000000659 · PMID:34524172 · W3201584613
review OA: closed CC0 ⤵ 1 in-corpus citation
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-08 ⓘ

This review examines current evidence for selective progesterone and androgen receptor modulators as treatments for benign gynecologic diseases like uterine fibroids and endometriosis.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Common benign gynecologic conditions such as uterine fibroids and endometriosis are linked to chronic pelvic pain, abnormal and heavy uterine bleeding, and infertility. Effective medical management of these diseases is an unmet need. The steroid hormones progesterone (P4), estrogen (E2), and testosterone play a major role in reproductive physiology and uterine pathologies. Notably, selective progesterone receptor modulators have shown considerable promise as treatment options for some hormone-dependent conditions. More limited data are available regarding the safety and efficacy of selective androgen receptor modulators. In this report we review current evidence for selective progesterone receptor modulators and selective androgen receptor modulators as treatment options for benign gynecologic conditions.

My notes (saved in your browser only)

Condition tags

endometriosischronic_pelvic_paininfertility

MeSH descriptors

Genital Diseases, Female Genital Diseases, Female Female Humans Progesterone Receptors, Androgen Receptors, Androgen Receptors, Progesterone

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (92)

Cited by (1)

Source provenance

europepmc
last seen: 2026-06-04T01:30:01.192114+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:24:20.309598+00:00
unpaywall
last seen: 2026-06-04T02:00:05.705006+00:00
License: CC0 · commercial use OK